Searchable abstracts of presentations at key conferences on calcified tissues

ba0007p176 | (1) | ICCBH2019

Prevalence of vitamin D deficiency in newly diagnosed children with cancer

Kecskemethy Heidi , Su Annelise , Bachrach Steven , Fullmer Michell

Objectives: 1) To determine the prevalence of Vitamin D deficiency in children with newly diagnosed cancer; 2) Compare Vitamin D levels of children with and without cancer; 3) Evaluate race and sex differences in Vitamin D levels.Methods: IRB approved retrospective review of medical records from our pediatric tertiary care center from 2011–2018. Inclusion criteria were serum 25-OH D within 3 months of oncology diagnosis and other non-oncology diagno...

ba0006p162 | (1) | ICCBH2017

Nutritional rickets presenting to secondary care in children (<16 years) -- A UK surveillance study

Julies Priscilla , Pall Karina , Lynn Richard , Calder Alistair , Mughal Zulf , Shaw Nicholas , McDonnell Ciara , McDevitt Helen , Blair Mitchell

Objectives: Rickets is a disease of growing children with potentially serious short and long-term complications. The United Kingdom (UK) national incidence of Nutritional Rickets(NR) is unknown and thought to be increasing. This study aims to describe the incidence, presentation and clinical management of children with NR in the UK and Republic of Ireland.Methods: Data is being collected prospectively monthly between March 2015 and March 2017 from 3500 p...

ba0001pp311 | Osteoporosis: evaluation and imaging | ECTS2013

Appropriate osteoporosis treatment by family physicians in response to FRAX vs caroc reporting: a randomized controlled trial

Beattie Karen , Ioannidis George , MacDermid Joy , Grewal Ruby , Papaioannou Alexandra , Hodsman Anthony , Adachi Jonathan D

Introduction: Current Canadian clinical practice guidelines recommend the FRAX or Canadian Association of Radiologists and Osteoporosis Canada (CAROC) fracture risk assessment tools to report 10-year fracture risk in an individual. CAROC considers sex, age, BMD and previous fracture as risk factors. It is unknown whether one reporting system is more effective in helping general practitioners (GPs) identify individuals who should be recommended for pharmacological treatment. We...

ba0005p469 | Other diseases of bone and mineral metabolism | ECTS2016

FGF23 and vitamin D metabolism in chronic kidney disease – mineral bone disorder

Piec Isabelle , Chipchase Allison , Nicholls Holly , Washbourne Christopher , Tang Jonathan , Fraser William D.

Fibroblast growth factor-23 (FGF23) is a major regulator of phosphate metabolism often elevated in genetic hypophosphataemic disorders and in chronic kidney disease–bone mineral disorder (CKD–BMD). Recent studies have identified relationships between FGF23 and vitamin D.Objectives: To determine the relationship between vitamin D and FGF23 metabolism in CKD.Method: We used randomized samples from patient...

ba0006p161 | (1) | ICCBH2017

Early-life vitamin D status and bone mass at five years in a prospective birth cohort study

Chaoimh Carol ni , Murray Deirdre , Kenny Louise , Irvine Alan , Hourihane Jonathan , Kiely Mairead

Objective: We aimed to investigate associations between early-life vitamin D status, mode of infant milk-feeding and bone outcomes at five years.Methods: Participants were from the prospective mother-infant SCOPE-BASELINE Birth Cohort Study. Serum 25 hydroxyvitamin D (25(OH)D) concentrations were quantified at 15 weeks gestation, in umbilical cord sera and at two and five years using a gold-standard CDC-accredited LCMS method. Whole-body bone mineral con...

ba0007oc25 | (1) | ICCBH2019

TransCon CNP: Potential for a once weekly novel therapy in children with achondroplasia

Bharucha Kamal , Ota Sho , Christoffersen Eva Dam , Mygind Per , Viuff Dorthe , Leff Jonathan

Objectives: Achondroplasia (ACH), the most common form of human dwarfism, is caused by a gain-of-function mutation in the fibroblast growth factor receptor 3 (FGFR3) gene, a key negative regulator of endochondral ossification. C-type natriuretic peptide (CNP) inhibits the FGFR3 pathway and thereby promotes proliferation and differentiation of chondrocytes to promote bone growth. TransCon CNP is a prodrug designed to provide continuous exposure to CNP to optimize efficacy with ...

ba0007p91 | (1) | ICCBH2019

Bone health index by hand X-ray compared with bone mineral density by dual-energy X-ray absorptiometry in children with Duchenne muscular dystrophy

Bowden Jonathan J , Krishnamurthy Ramkumar , Hu Houchun , Adler Brent , Krishnamurthy Rajesh , Bowden Sasigarn A

Objectives: Children with Duchenne muscular dystrophy (DMD) receiving long-term glucocorticoid (GC) therapy are at risk for osteoporosis and fragility fractures. Recent studies showed that cortical thickness and areas were associated with increased fracture risk. Digital X-ray measurement of the cortical thickness of the metacarpal bones has a potential role as a marker for bone health in children, but has not been evaluated in DMD. The aim of this study was to compare bone ag...

ba0001pp459 | Other diseases of bone and mineral metabolism | ECTS2013

Correlates of tissue mineral density of bone samples from total hip arthroplasty patients with type 2 diabetes: an ex vivo study

Pritchard Janet , Papaioannou Alexandra , Hurtig Mark , Giangregorio Lora , Atkinson Stephanie , Beattie Karen , Adachi J.D. , DeBeer Justin , Winemaker Mitchell , Avram Victoria , Schwarcz Henry

Introduction: Fracture risk is greater for adults with type 2 diabetes (T2D), despite normal or higher areal bone mineral density (aBMD) compared to controls. Tissue mineral density (TMD), measured by microCT, is more representative of actual mineral density than in vivo aBMD. The aim of this study was to determine whether TMD is greater in adults with T2D, and to investigate the correlates of TMD in adults with T2D.Methods: Using proximal femur...

ba0001oc5.5 | Treatment of osteoporosis | ECTS2013

Bone anabolic efficacy and safety of ba058, a novel analog of hPTHrP: 12-month extension data from a phase 2 clinical trial in postmenopausal women with osteoporosis

Hattersley Gary , Bilezikian John , Guerriero Jonathan , Kumar Prasanna , Zanchetta Jose , Lyttle C Richard , O'Dea Louis Saint L

A randomized, placebo-controlled phase 2 study evaluated the safety and efficacy of BA058, an analog of hPTHrP(1–34), in postmenopausal women with severe osteoporosis. 221 patients were randomized to received BA058 20, 40, and 80 μg, placebo or teriparatide (TP) 20 μg, by daily s.c. injection. 184 (83%) patients completed an initial 24 weeks of treatment. The mean percent change in lumbar spine BMD at 24 weeks was 1.6% with placebo, 6.7% with BA058 80 μg, a...

ba0005ni6 | Abstract Presentations | ECTS2016

Multi-potency and immunosuppressive activity of mesenchymal stromal cells derived from human induced pluripotent stem cells

Roux Clemence , Saviane Gaelle , Pini Jonathan , Dihib Gihen , Nourhene Belhaid , Wakkach Abdel , Blin-Wakkach Claudine , Rouleau Matthieu

Tissue healing/reconstruction as well as exacerbated inflammatory diseases may benefit from stem cell based therapies. Ex vivo isolated tissue mesenchymal stromal cells (MSCs) displaying multi-potent activity and immune-regulatory functions were long ago proposed as therapeutic cells and already tested in many clinical assays. Nevertheless, their use may be restricted because of the few number that can be recovered from adult tissues, their limited in vitro e...